BI Asset Management Fondsmaeglerselskab A S Sells 34,810 Shares of Bristol Myers Squibb Company $BMY

BI Asset Management Fondsmaeglerselskab A S lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 15.2% during the 4th quarter, HoldingsChannel reports. The firm owned 194,483 shares of the biopharmaceutical company’s stock after selling 34,810 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Bristol Myers Squibb were worth $10,490,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares in the last quarter. State Street Corp lifted its stake in Bristol Myers Squibb by 2.0% in the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after acquiring an additional 1,855,238 shares in the last quarter. Geode Capital Management LLC lifted its stake in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Norges Bank bought a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $1,947,272,000. Finally, Bank of New York Mellon Corp lifted its stake in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.05% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have commented on BMY. Barclays began coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price on the stock. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Bank of America cut their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Up 1.1%

Shares of Bristol Myers Squibb stock opened at $57.24 on Friday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The stock has a market cap of $116.88 billion, a P/E ratio of 16.08, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business’s 50 day moving average is $58.10 and its 200-day moving average is $56.52.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business posted $1.80 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.